Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia.
about
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesIdentification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugsProlonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.Fludarabine in Waldenstrom's macroglobulinemia.Mobilization characteristics and strategies to improve hematopoietic progenitor cell mobilization and collection in patients with chronic granulomatous disease and severe combined immunodeficiencyVariant rs1801157 in the 3'UTR of SDF-1ß does not explain variability of healthy-donor G-CSF responsivenessHematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.Follicular lymphoma: today's treatments and tomorrow's targets.Recent advances in chronic lymphocytic leukemia.Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment.Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical issues.A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.Chemomobilization with high-dose etoposide and G-CSF results in effective and safe stem cell collection in heavily pretreated lymphoma patients: report from a single institution study and review.Advances in stem cell mobilization.Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean mulThe effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo OsseoFludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02).The efficacy and stem cell toxicity of cladribine and rituximab in the treatment of patients with chronic lymphocytic leukemia: are all purine analogs created equal?Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis.Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.Single Dose Preemptive Plerixafor for Stem Cell Mobilization for ASCT After Lenalidomide Based Therapy in Multiple Myeloma: Impact in Resource Limited Setting.Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases.Feasibility of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
P2860
Q28290236-676811E2-9494-4DC0-A4B5-BA2AEBE8541FQ28533669-7344E38D-A5CC-4685-812D-1236E2E2034DQ33383571-82122E29-A131-478F-86B0-A085803ED220Q34351916-D51649B3-CDF4-4DE9-BFAC-879586D977F1Q35091493-DA6ABB19-E4B5-4509-BA20-ED90257CFE30Q35213695-6F07466C-C234-4FE1-AF9A-1E738E1C9C53Q36428104-17095B78-BB76-452E-AF97-0CDF0787ECB9Q36521854-0EF3556A-1812-4AD4-80C6-4A41C9398471Q36523498-0D3C90CB-1FB7-440D-92D0-D887681AA7DCQ36794316-C3F3A154-C464-4DC8-9C01-1A82BB62B091Q37053190-00FBDE36-3826-4454-8C27-4DDFE2D19BBCQ37738995-FF085E79-04F1-472C-AFC5-596514A5480AQ37899223-E0E89DEB-0E61-412E-96C0-6B5CE91C956EQ38160461-CC2EA3D2-9150-4205-AA74-FD911D58E3D4Q38176669-007A594B-57CF-49ED-9CAD-5743CE1216AEQ38183225-2967E969-A06F-4FD6-8F1B-DD7D5CC4EE74Q38418369-FDFD05DC-3B1E-4AD6-94B9-03D3CFDBA217Q39049318-DF539D36-92B0-432C-B330-5829598B34FDQ42592824-52834B45-31BF-48C7-90C4-2BCAC335ACC3Q42861257-415C14A2-0162-4DFD-9B6A-4DBE1743077FQ43135383-37CA848C-6BA2-4FEA-8513-19134A6BD529Q43168894-60185404-7227-4CF6-BFF7-62A9AD0CDB5EQ46389738-1A2ECC5E-8806-44B3-991D-6B9237A51B11Q46668187-F2A9B905-0F12-404F-997F-E7B51226D70AQ46925369-4CBA7258-1DA2-4B7C-8841-EE8386DEE095Q48333236-36F1A5B3-88DA-49B6-88A4-D12C5DD29D24Q50092819-923EF1F2-7423-4355-9F33-8AD6F2722F97Q51199274-252DABFB-8725-43FA-89C5-DC29929DFE56Q52884713-7EBEF8BC-B9B7-4A9B-BDAF-D776E47D4429Q53600019-977497DF-1E36-4468-8061-DAFC0460434F
P2860
Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Impact of frontline fludarabin ...... chronic lymphocytic leukemia.
@ast
Impact of frontline fludarabin ...... chronic lymphocytic leukemia.
@en
Impact of frontline fludarabin ...... chronic lymphocytic leukemia.
@nl
type
label
Impact of frontline fludarabin ...... chronic lymphocytic leukemia.
@ast
Impact of frontline fludarabin ...... chronic lymphocytic leukemia.
@en
Impact of frontline fludarabin ...... chronic lymphocytic leukemia.
@nl
prefLabel
Impact of frontline fludarabin ...... chronic lymphocytic leukemia.
@ast
Impact of frontline fludarabin ...... chronic lymphocytic leukemia.
@en
Impact of frontline fludarabin ...... chronic lymphocytic leukemia.
@nl
P2093
P1433
P1476
Impact of frontline fludarabin ...... chronic lymphocytic leukemia.
@en
P2093
Alain Delmer
Bernard Grosbois
Bruno Cazin
Bruno Villemagne
Dominique Bastit
Florence Villard
Frederic Maloisel
Geraud Manhès
Karim Belhadj
Karim Maloum
P304
P356
10.1182/BLOOD-2003-05-1449
P407
P577
2003-09-11T00:00:00Z